



Quarterly Update

November 7, 2017

Dear Stockholders,

Our (unaudited) third quarter financial results are now available. The total revenue for the third quarter of 2017 was \$975,000 compared to \$563,000 for the same period in 2016. The increase in revenue corresponds with increases in both royalties and peptide sales. Gross profits for the third quarter of 2017 were \$777,000 compared to \$491,000 for the same period in 2016. Operating expenses for the third quarter of 2017 were \$589,000 compared to \$704,000 for the third quarter of 2016. Consequently, we showed a profit of \$188,000 for the third quarter of 2017 compared to operating losses of (\$213,000) in the third quarter of 2016. The company's non-cash stock expense fluctuates substantially from quarter to quarter. As a result, the company's management and board of directors exclude this expense from our operating expenses and from our operating losses during our internal analysis of the company's performance. This information has been added to the table below.

Select Financial Highlights (000's)

| <i>Item</i> | 3Q 2017 | 3Q 2016 |
|--------------------------------|----------------|----------------|
| <i>Revenue</i> | \$975 | \$563 |
| <i>Gross Profits</i> | \$777 | \$491 |
| <i>Operating Expenses</i> | \$589 | \$704 |
| <i>Excluding Stock Expense</i> | \$527 | \$619 |
| <i>Operating profit (loss)</i> | \$188 | (\$213) |
| <i>Excluding Stock Expense</i> | \$250 | (\$128) |
| Cash + A/R – A/P | \$2,799 | \$2,481 |

Our most important revenues are generated from our high margin licensing agreements and consumer product sales. Our licensing revenues are royalty-based and, therefore, carry no cost of goods. While royalty payments appear to be "pure profit," we must measure this royalty income against the costs required to support our ongoing patent obligations and the development/production costs required to support our licensing partners and generate new pipeline opportunities.

Our licensees for personal care peptides, Evonik and Grant Industries each have increased their marketing presence this year as well and we are encouraged that this will help grow their peptide sales.

The company's research and development efforts remain focused on generating peptides that have near term commercialization potential as well as longer term pipeline opportunities. During the quarter, we continued to grow our intellectual property portfolio. We continue our efforts in our early drug discovery program with peptides for psoriasis.

Apotheder[®]m products will be launching two new gift sets just in time for the holiday season.

The overall direction of the company continues to be positive. We look forward to keeping you informed of our progress. The demand for high quality peptides from our partners continues to be strong. We continue to remain optimistic that we will see year-over-year gross product growth while exercising financial discipline in the management of our expenses.

Sincerely,



Robin L. Carmichael
President & Chief Executive Officer



R. Stephen Beatty
Executive Chairman of the Board
Chief Investor Officer

Please take note:

AST (our stock transfer agent) has advised us that some of our stockholders did not submit their letter of transmittal when we performed our reverse split in 2012 and therefore, the state you resided in at the time of the reverse split, will begin escheatment process on your stock. This essentially means that if you did not turn in the letter of transmittal, the state will claim your non exchanged Helix Biomedix stock. You will also start receiving letters from LINK asking you to pay a fee to exchange your shares. If your stock is escheated in the future, please go to your state's unclaimed property website to reclaim your shares back. **In order to avoid escheatment, we strongly suggest that you submit your letter of transmittal to avoid the issue by contacting AST directly. You can either call AST or send an email to request a duplicate Letter of Transmittal for the unexchanged shares of Helix BioMedix.**

| | |
|--|---|
| Shareholder Services: (AST's Call Center is open Monday through Friday, 8am to 8pm ET. | (800) 937-5449 (718) 921-8124 or Email directly at info@amstock.com |
|--|---|



Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. In 2015 Evonik's more than 33,500 employees generated sales of €13.5 billion and adjusted EBITDA of €2.47 billion. The adjusted EBITDA margin was 18.2 percent and ROCE was 16.6 percent. More than 80 percent of sales are generated outside Germany.



www.apothederm.com



DEDICATED TO SUPERIOR QUALITY & CUSTOMER SERVICE

Founded in 1938, Grant Industries is a privately held company involved in the research, development, manufacturing, and marketing of specialty performance chemicals. A leading global provider to the personal care industry, Grant Industries dedicates its business on superior quality and customer service. Operations are conducted out of two main facilities; Grant Industries-USA in Elmwood Park, NJ and Grant Industries-Asia in Beijing, China. Its worldwide distribution network covers all key markets in the Americas, Europe, the Middle East, Africa, Asia, and Australia.